Why the study?
Beta-2-microglobulin has been suggested as an emerging biomarker for CVD and mortality, but summarized evidence on these associations was needed.
Does higher baseline beta-2-microglobulin associate with increased cardiovascular events and mortality in general populations or patients with renal disease?
Does higher baseline beta-2-microglobulin associate with increased cardiovascular events and mortality in general populations or patients with renal disease?
Answers are grounded in this paper and cite their sources.
Beta-2-microglobulin is moderately associated with cardiovascular events and mortality, highlighting its potential as a risk biomarker.
BACKGROUND AND AIMS: Beta-2-microglobulin (B2M) has been suggested as an emerging biomarker for cardiovascular diseases (CVD), including coronary heart disease (CHD) and stroke, and mortality. METHODS: Three databases were searched from inception to January 2, 2020, supplemented by scanning reference lists of identified studies. We identified studies that reported associations of baseline serum or plasma B2M and CVD incidence, CVD mortality, or CHD and stroke separately, in either general populations or patients with renal disease. Relative risks (RR) were extracted and harmonized to a comparison of the highest versus lowest third of the distribution of B2M, and the results were aggregated. RESULTS: = 83.1%) for infectious mortality. CONCLUSIONS: Available observational data show that there are moderate positive associations between B2M levels and CVD events and mortality, although few studies have been conducted in general populations.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: